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Superparamagnetic iron oxide nanoparticles (MNPs) together with magnetic resonance imaging (MRI) are the 
preferred tools for monitoring the fate and biodistribution of administered cells in stem cell therapy studies. 
Commercial MNPs need transfection agents and long incubation times for sufficient cell labeling and further in 
vivo cell detection. In this work, we have synthesized MNPs coated with pluronic F127 and tetronic 908, and 
validated their applicability as contrast agents for MRI cell detection on two different cell types: rat mesenchy-
mal stem cells (MSCs) and multipotent neural progenitor cell line from mice (C17.2). No transfection agent was 
needed for a complete MNP internalization, and the uptake was only dependent on MNP concentration in medium 
and limited on the incubation time. By combining in vivo MRI and ex vivo histology microscopy, we have dem-
onstrated the MRI signal detected corresponded exclusively to labeled cells and not to free particles. Pluronic 
F127- and tetronic 908-coated MNPs represent promising contrast agents for stem cell tracking due to their 
ease of use in preparation, their efficiency for cell labeling, and their high sensitivity for in vivo cell detection.
Key words: Mesenchymal stem cells (MSCs); Magnetic resonance imaging (MRI); Cell tracking; 
Superparamagnetic nanoparticles; Intraparenchymal administration
INTRODUCTION
Cell transplantation has shown promising results in 
experimental models of several diseases such as stroke 
with several types of cells; however, the mechanisms 
that mediate the recovery are less understood (11,16,52). 
Integration into host tissue, immunomodulation processes, 
or growth and trophic factor secretion are possible modes 
of action; however, fundamental questions related to bio-
distribution or fate remain partially unanswered (11,44). 
Cell tracking and imaging can help in bridging these 
open gaps. In the field of cell imaging, several non-
invasive techniques for in vivo studies have been devel-
oped; however, magnetic resonance imaging (MRI) 
combined with contrast agents as superparamagnetic iron 
oxide nanoparticles (MNPs) has the highest potential to 
meet the required resolution (2,10,39). Several types of 
MNPs have been developed in last years, with the aim 
of finding the best balance between low cytotoxicity, 
cell detection, and tagging efficiency, the last one mainly 
being influenced by the coating. Dextran is one of the 
most commonly used coatings (9,36); however, cellular 
labeling with dextran-coated nanoparticles requires the 
use of transfection agents, such as poly-l-lysine or lipo-
fectamine, for an efficient cell tagging, which can result 
in toxic side effects depending on their concentration 
(3,27,38,47). The use of MNPs, however, is not only lim-
ited to cell tracking but also includes theranostic applica-
tions, as shown by use in tumor detection and therapy 
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(24,43), where other polymeric coatings have been used 
(20–22,51,53). In this regard, MNPs stabilized with block 
copolymers, such as pluronic F127 (P127) or tetronic 908 
(T908), have emerged as efficient formulations for tumor 
imaging and macrophages labeling (20), but their use for 
in vivo stem cell tracking remains largely unexplored.
With this purpose, in this study, we synthesized MNPs 
coated with P127 and T908 and validated their applica-
bility as in vivo contrast agents for MRI cell detection 
on two different cell types employed in cell therapy: rat 
mesenchymal stem cells (MSCs) and a multipotent neu-
ral progenitor cell (NPC) line from mice (C17.2) after an 
intraparenchymal administration.
MATERIALS AND METHODS
Cell Lines
MSCs (Cultrex; Trevigen, Gaithersburg, MD, USA) 
were cultured in Iscove’s modified Dulbecco’s medium 
(IMDM; 78%), fetal bovine serum (FBS; 10%), horse 
serum (10%), penicillin–streptomycin (1%) (Gibco, Paisley, 
UK), and amphotericin-B (1%) (Sigma-Aldrich, St. Louis, 
MO, USA). Cell passage numbers between 7 and 18 were 
used. C17.2 cells were provided by Dr. Markus Aswendt 
and Prof. Mathias Hoehn (Max-Planck Institute, Cologne, 
Germany) and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM; 78%), FBS (10%), horse serum (5%), 
penicillin–streptomycin (1%) (Gibco), and amphotericin-B 
(1%) (Sigma-Aldrich).
Synthesis and Characterization of P127- 
and T908-Coated Superparamagnetic Nanoparticles
P127- and T908-coated magnetic nanoparticles were 
prepared through a two-step procedure following a proto-
col described elsewhere (21) with several modifications. 
Briefly, in order to form the magnetic core, aqueous solu-
tions of 0.1 M Fe(III) (Sigma-Aldrich) and 0.1 M Fe(II) 
(Sigma-Aldrich) in a volume ratio 2:1 were mixed (stir-
ring ratio, 400 rpm) under N2 atmosphere and room tem-
perature (RT). Ammonium hydroxide (5 ml, 5M) (Merck, 
Darmstadt, Germany) was added dropwise to produce the 
particles. After 10 min, 46 μl of oleic acid (OA) (Sigma-
Aldrich) was added, and the temperature was raised to 
80°C and maintained for 20 min under an N2 atmosphere. 
The solution was cooled down to RT, and the suspen-
sion was washed for magnetic separation using distilled 
water (DW) (pH 9.5). Then 5.5 mg of nanoparticles in 
4 ml of chloroform (Sigma-Aldrich) was sonicated for 
5 min. This solution was mixed with 40 mg of polymer 
and stirred for 5 min. After chloroform evaporation, DW 
was added and the mixture was placed on a shaker for 1 h. 
MNPs were washed three times with DW and separated 
using a 0.2-T magnet.
A structural analysis of the magnetic cores was per-
formed by transmission electron microscopy (TEM) and 
X-ray diffraction (XRD) data. A dried drop of OA-coated 
MNPs was measured on a TEM microscope (Philips 
CM-12; Bend, OR, USA) operating at 120 kV and with 
a Philips powder diffractometer fitted with Philips 
PW1710 control unit, vertical Philips PW1820/00 goni-
ometer, and FR590 Enraf Nonius generator (Rotterdam, 
The Netherlands), respectively. Nanoparticle shape was 
determined by circularity determination of 210 nano-
particles using ImageJ software [http://imagej.nih.gov/ij/; 
National Institutes of Health (NIH), Bethesda, MD, 
USA]. The nanoparticle circularity value was defined as 
4pA/P2, where A is the particle area and P is its perim-
eter, and approaches 1 for an ideal circle. Particles with 
circularities of 0.25 or below may be considered aggre-
gates or artifacts in the size analysis. Magnetic properties 
of the nanoparticle cores were recorded on a vibrating 
sample magnetometer (VSM) (Quantum Design Inc., 
San Diego, CA, USA). The iron content was determined 
by inductive coupled plasma optical emission spectros-
copy (ICP-OES) (Varian Medical Systems, Palo Alto, 
CA, USA), and the mean hydrodynamic particle size was 
measured using a dynamic light scattering (DLS) ALV-
5000F (ALV-GmbH, Langen, Germany) instrument with 
vertically polarized incident light (488 nm) supplied by 
a diode-pumped Nd:yAG solid-state laser (Coherent Inc., 
Santa Clara, CA, USA). Zeta potentials of polymer-
coated MNPs were measured using a Zetasizer Nano ZS 
instrument (Malvern Instruments Ltd., Malvern, UK) 
equipped with a red laser (633 nm) in backscatter mode at 
25°C. Polymer adsorption onto the cores was confirmed 
by Fourier transform infrared spectroscopy (FTIR) with 
a FTIR spectrometer (FTIR 670; Varian Inc.) and quanti-
fied by thermal gravimetric analysis (TGA) on a Q5000IR 
(TA Instruments, New Castle, DE, USA).
Cell Labeling With MNPs
For cell labeling, two different MNP concentrations, 
35 and 15 μg/ml, and two cellular incubations times, 24 
and 6 h, were studied (n = 6).
Both cell types were labeled following a protocol 
described elsewhere (48) with slight modifications. After 
coincubation of MNPs and cells, the MNP-containing 
medium was removed, and cells were washed three times 
with 1.5 ml of phosphate-buffered saline (PBS; without 
Mg2+ and Ca2+; Gibco) to remove nonattached MNPs. 
After washing, the cells were left for 12 h in 1 ml of fresh 
label-free medium. Next, medium was removed, cells 
were washed once with 1.5 ml of PBS, and 0.5 ml of 
ethylenediaminetetraacetic acid (EDTA)–trypsin (Gibco) 
was added to detach the cells from the well. The trypsin 
was neutralized with fresh medium, and the detached cells 
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were collected in a 50-ml tube (BD Falcon, Bedford, MA, 
USA). After a mild centrifugation (12 × g), the super-
natant was discarded and the cells were resuspended in 
fresh medium.
Cell Labeling With CellTraceTM CFSE
CellTrace CFSE is a stable, well-retained fluorescent 
label normally used to monitor distinct generations of 
proliferating cells by dye dilution (41). However, in this 
study, CFSE enabled the histological detection of adminis-
tered cells. After labeling with MNPs and 2 h prior to the 
administration, the cell medium was removed and CFSE 
labeling was performed by following the manufacturer’s 
protocol (CellTracer CFSE Cell Proliferation Kit for flow 
cytometry; Invitrogen, Paisley, UK). In short, cells were 
incubated with 2 μl of CFSE in 2 ml of 37°C PBS for 
15 min. Then PBS was removed, and fresh medium was 
added for a further incubation of 45 min.
Cell Count Determination
To determine the influence of the labeling on the cellu-
lar proliferation, total cell count was performed with try-
pan blue staining (STEMCELL Technologies, Grenoble, 
France) and a Neubauer counting chamber (Blaubrand; 
Sigma-Aldrich). Samples were diluted 1:5 with PBS and 
1:2 with trypan blue. Cell count was performed by using 
an inverted microscope (Olympus IX51; Tokyo, Japan).
Cell Viability Assay
For assessing the viability of the cells after labeling, 
supernatants from the last 12-h incubation step were col-
lected, including a negative control of lysed cells. Cell 
viability was determined by means of a lactate dehy-
drogenase assay (LDH) (Sigma-Aldrich), following the 
manufacturer’s protocol. In brief, supernatants were cen-
trifuged at 12 × g for 5 min and further incubated with LDH 
reagents for 20 min. Next, the plate was read in a Synergy2 
microplate reader (Biotek Instruments, Winooski, VT, 
USA) at 490 nm, and the viability rate was calculated with 
respect to control and lysates values.
Intracellular Iron Determination
Iron uptake per cell was quantified by dissolving 
100,000 cells in 1 ml of HCl 37% extra pure (Merck). 
DW was added to reach a total volume of 5 ml. Iron con-
centration was determined by ICP-OES (Varian Inc.). 
The intensity of the emission line at 238.204 nm was 
measured for iron and compared to a standard solution.
Prussian Blue Staining
Prussian blue staining was performed to demonstrate 
the uptake of the MNPs by the cells. Labeled cells were 
plated and after 8 h were washed with PBS and incubated 
for 20 min with a mixure of equal part of aqueous solu-
tion of 20% HCl 37% extra pure and aqueous solution of 
10% potassium ferrocyanidetrihydrate [KFe(CN)6·3H2O, 
FW 422.2; Sigma-Aldrich]. After incubation, cells were 
washed three times with PBS, and images were taken 
using an inverted microscope (Olympus IX51).
Transmission Electron Microscopy
To assess the localization of the MNPs in the cell, TEM 
images of the cells were taken. Fixation and postfixation 
of 5 × 105 cells were performed in 2% glutaraldehyde 
(Sigma-Aldrich) and in 1% osmium tetroxide (OsO4) 
(Sigma-Aldrich), in sodium cacodylate buffer (Sigma-
Aldrich), respectively. Inclusion was done in Spurr’s 
epoxy resin (Sigma-Aldrich). Semithin sections (0.5 μm) 
were stained with toluidine blue (Sigma-Aldrich), and 
ultrathin sections (100 nm) were stained with uranyl ace-
tate (Sigma-Aldrich) and lead citrate (Sigma-Aldrich).
Animal Studies
All experimental protocols involving the use of research 
animals were approved by the institutional ethics commit-
tee of the Hospital Clínico Universitario of Santiago de 
Compostela and were performed according to the guide-
lines of the Animal Welfare Committee of the Hospital 
Clínico Universitario of Santiago de Compostela and in 
accordance with applicable legislation of the European 
Union (86/609/EEC, 2003/65/EC, 2010/63/EU, RD 1201/ 
2005, and RD 53/2013).
A total of two male Sprague–Dawley rats (Harlan 
Laboratories, Barcelona, Spain) weighing 285 and 300 g, 
respectively, were used in this study. Animals were kept in 
a controlled environment at 22 ± 1°C and 60 ± 5% humid-
ity, with 12:12-h light/darkness cycles. Animals were fed 
ad libitum with standard diet pellets and tap water. All sur-
gical procedures and MRI studies were conducted under 
sevofluorane (Abbott Laboratories, Lake Bluff, IL, USA) 
anesthesia (3–4%) using a carrier 65:35 gas mixture of 
N2O/O2. To study the in vivo contrast introduced by the 
designed MNPs in the rat brain, intraparenchymal injec-
tions of 10 μl of 50,000 P-MNP- or T-MNP-labeled MSCs 
in PBS were performed through a hole drilled into the 
skull of the animals. MRI scans were performed immedi-
ately after cell injections.
Briefly, rats were placed in a stereotaxic frame (Stoelting 
Co., Wood Dale, IL, USA) under sevoflurane anesthe-
sia. A 1-cm-long midline incision was made in the scalp, 
beginning midway between the eyes and terminating 
behind the lambda. A cotton swab was used to clear away 
the soft tissue covering the skull. A Hamilton syringe 
(10 μl; Hamilton, Reno, NV, USA) was filled with 10 μl 
of 50,000 P-MNP- or T-MNP-labeled MSCs and mounted 
onto the injection pump, and the needle was positioned 
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directly over the bregma. The x, y, and z axis coordinates 
were all set to zero. The needle was then positioned at 
the entry point, +0.6 mm anterior and −2.9 mm lateral 
of the bregma to the right. A small cranial burr hole was 
drilled through the skull at the entry point. The needle 
was slowly inserted into the basal ganglia to a depth of 
5.5 mm below the surface of the skull, and labeled cells 
were injected at a rate of 0.1 μl/min over 10 min. The nee-
dle was left in place for 10 min and then removed at a rate 
of 1 mm/min to prevent the reflux of cells and blood. The 
burr hole was filled with bone wax (Ethicon, Somerville, 
NJ, USA), and the scalp incision was closed.
Magnetic Resonance Imaging
MRI studies were conducted on a 9.4-T MR system 
(Bruker Biospin, Ettlingen, Germany) with 440 mT/m 
gradients. A quadrature radiofrequency transmit–receive 
resonator was used for data acquisition.
For P-MNP and T-MNP MRI and further relaxivity 
determinations, agar phantoms were made following a 
procedure described elsewhere (48) with different concen-
trations of P-MNPs (0.36, 0.18, 0.09, and 0.04 mM) and 
T-MNPs (0.45, 0.22, 0.11, and 0.06 mM). T2 weighting 
was achieved by using a multislice multiecho spin-echo 
(MSME) sequence with the following acquisition param-
eters: field-of-view (FOV) of 7.5 cm × 7.5 cm, echo time of 
7.32 ms, repetition time of 5.4 s, 16 echoes (incremented 
by 7.32 ms), 14 slices, and 1 average. Postprocessing 
using ImageJ software (http://imagej.nih.gov/ij/; NIH) 
enabled the calculation of relaxation time (T2), relaxation 
rate (R2), and relaxivity (r2) determination.
For MRI of labeled cells, agar phantoms with 100,000 
cells per condition were scanned. T2*-weighted MRIs 
were acquired using a multigradient echo (MGE) sequence 
with a 4.44-ms echo time, 6.75-ms echo spacing, 1.8-s 
repe tition time, 16 echoes, 14 slices, 2 averages, FOV of 
7.5 cm × 7.5 cm, and matrix size of 256 × 256. Postprocessing 
was performed using ImageJ software (http://imagej.nih.
gov/ij/; NIH) For in vivo cell detection, MRIs were acquired 
using a cross-coil setup, consisting of a linear birdcage reso-
nator of 7-cm diameter, for transmission, and a 2 × 2 arrayed 
surface coil for signal detection (both from Bruker Biospin). 
T2*-weighted MRIs were acquired with the same param eters 
as for the phantom study. Postprocessing was performed 
using ImageJ software (http://imagej.nih.gov/ij/; NIH).
Ex Vivo Analysis
Animals were deeply anesthetized and transcardially 
perfused with 100 ml of PBS (0.1 M, pH 7.4) and 150 ml 
of 4% formaldehyde (VWR Chemicals, Leuven, Belgium) 
immediately after MRI studies. Brains were carefully 
removed from the skull and sectioned in 2-mm slices in a 
matrix. Slices were postfixed by immersion in 4% formal-
dehyde overnight, dehydrated, and embedded in 4% paraffin 
(VWR International a/s, Albertslund, Denmark). Prussian 
blue staining was performed to detect MNP-labeled cells 
in brain parenchyma, and fluorescence microscopy images 
were taken to determine the CFSE-labeled cell localization 
(Olympus IX51).
Statistical Analysis
Results were expressed as mean ± standard devia-
tion (SD). Statistical analyses were performed using a 
Student’s t-test or one-way analysis of variance (ANOVA) 
followed by Bonferroni post hoc test to compare cell 
count and viability between groups. A valued of p < 0.05 
was considered statistically significant. The statistical 
analysis was conducted using PASW Statistics 18 for 
Mac (IBM, Armonk, Ny, USA).
RESULTS
Pl127- and T908-Coated Superparamagnetic 
Nanoparticle Characterization
Magnetic cores coated with OA were obtained through 
the chemical coprecipitation method, with a mean circu-
larity of 0.87 ± 0.17 and core size of 8.6 ± 1.4-nm diameter 
as determined by TEM (Fig. 1A), of 7.7 ± 0.8-nm diam-
eter as determined by XRD spectroscopy (Fig. 1B), and 
of 7.3 ± 0.8-nm diameter as determined by DLS. The core 
crystal structure determination using the XRD spectrum 
showed peaks at 2q positions of 30.2°, 35.6°, 43.2°, 57.1°, 
and 62.7°, corresponding to the 220, 311, 400, 511, and 
440 planes of magnetite, respectively, with a lattice param-
eter of 8.361 ± 0.004 Å (Fig. 1B). Data obtained through 
VSM measurements showed that the cores exhibited super-
paramagnetic behavior at RT (Fig. 1C). For further nanopar-
ticle surface functionalization, the presence of attached OA 
was evaluated through TGA. Two peaks were observed at 
180°C and slightly above 200°C, corresponding to a mass 
loss percentage of 18% of OA. The main peak was observed 
at ca. 350°C with a 26 wt% of mass loss percentage corre-
sponding to block copolymers (Fig. 1D1).
Polymer coating was performed, and the hydrodynamic 
size measured by DLS was 154 ± 6 nm with a polydisper-
sity index of 0.076 nm for pluronic-coated nanoparticles, 
and 180 ± 6 nm with a polydispersity index of 0.015 nm 
for tetronic-coated nanoparticles, respectively. The Z poten-
tial of these coated particles dispersed in DW was nega-
tive for both, being −18 ± 3 and −24 ± 3 mV, respectively. 
TGA of pluronic-coated iron oxide nanoparticles showed 
the presence of the polymer and the OA (Fig. 1D2). 
Two peaks were observed at about 260°C (20 wt%) and 
310°C (35 wt%), close to OA and pure P127 boiling 
points, respectively. For T908-coated nanoparticles, the 
behavior was similar (Fig. 1D3), the first peak at about 
260°C (26%) corresponding to OA and the second peak 
at 310°C (42 wt%) corresponding to pure T908 were 
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detected. Polymer FTIR spectroscopy confirmed the 
adsorption of each block copolymers to the MNP surface 
(Fig. 1E1–1E3). Two broad peaks at approximately 440 
and 610 cm−1 corresponded to Fe-O vibration modes (8) 
and ca. 1,430 and 1,600 cm−1 specific for symmetric and 
asymmetric stretching vibrations of COO–, respectively 
(50). It was also possible to identify the asymmetric CH2 
and the symmetric CH2 stretching bands at 2,850 and 
2,920 cm−1, respectively. The main difference between 
the polymer coated and uncoated nanoparticles in FTIR 
data was the peak at 1,100 cm−1, typical for symmetric 
stretching vibrations of C–O–C bonds (19). MRI contrast 
in T2-weighted images of the four different concentra-
tions were measured. The relaxation rate (R2) was plotted 
versus iron concentrations, and a linear relationship was 
found between R2 and the MNP concentration, resulting 
in a transverse relaxivity (r2) of 398 ± 12 mM−1 s−1 for 
P127 and 330 ± 20 mM−1 s−1 for T908.
Figure 2. Prussian blue staining of MSCs and C17.2 cells. (A) Phase-contrast microscopy of P-MNP (35 μg/ml, 24 h)-labeled 
MSCs. (B) Bright-field microscopy of P-MNP (35 μg/ml, 24 h)-labeled MSCs. (C) Phase-contrast microscopy of T-MNP (35 μg/
ml, 24 h)-labeled MSCs. (D) Bright-field microscopy of T-MNP (35 μg/ml, 24 h)-labeled MSCs. (E) Phase-contrast microscopy of 
P-MNP (35 μg/ml, 24 h)-labeled C17.2. (F) Bright-field microscopy of P-MNP (35 μg/ml, 24 h)-labeled C17.2. (G) Phase-contrast 
microscopy of T-MNP (35 μg/ml, 24 h)-labeled C17.2. (H) Bright-field microscopy of T-MNP (35 μg/ml, 24 h)-labeled C17.2. 
Scale bar: 50 mm. Abbreviations: MSCs, mesenchymal stem cells; C17.2, multipotent neural progenitor cell line from mice; MNPs, 
superparamagnetic nanoparticles; P-MNPs, pluronic F127-coated superparamagnetic nanoparticles; T-MNPs, tetronic 908-coated 
superparamagnetic nanoparticles.
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In vitro Validation of P127- and T908-Coated 
Superparamagnetic Nanoparticles: Cellular 
Internalization of P-MNPs and T-MNPs 
in MSCs and C17.2
For investigating the labeling capacities of P127- and 
T908-coated superparamagnetic nanoparticles (P-MNPs 
and T-MNPs, respectively), two concentrations of nano-
particles and two incubation times were evaluated in two 
different cell types. Cell labeling without the use of trans-
fection agents was assessed by Prussian blue staining 
(Fig. 2). The tagging and the full cellular internalization 
of the nanoparticles were assessed by TEM for all experi-
mental conditions (Fig. 3). P-MNPs and T-MNPs were 
found encapsulated in endosomal structures distributed 
throughout the cytoplasm in both cell types.
Quantitatively, iron content, as determined by ICP-OES 
(Table 1 and Fig. 4A and B), showed that the internalized 
iron per incubation condition, as being between 36–39 pg 
Fe/cell and 9–16 pg Fe/cell for 24- and 6-h incubation 
times, respectively, for MSCs and between 17–39 pg 
Fe/cell and 8–14 pg Fe/cell for 24- and 6-h incubation 
times, respectively, for C17.2. On the basis of the TEM 
images and the iron internalization data, the MRI signal 
of labeled cells corresponded exclusively to internal-
ized MNPs. Relaxation rates R2* were calculated from 
T2* maps as R2* = 1/ T2*, resulting in relaxation rates R2* 
between 50 and 100 s−1 for all conditions (Fig. 4C and 
D). Signal changes for the first echo of MR T2*-weighted 
images can be easily observed in Figure 4E. Quantitative 
T2* maps were calculated by fitting pixel intensities of 
the MGE images to a monoexponential decay curve, on a 
pixel-by-pixel basis (Fig. 5).
The well-being of labeled cells with respect to con-
trol cells was evaluated by comparing the cell count and 
the viability using the LDH assay (Fig. 6). A significant 
reduction in proliferation was observed for the longest 
incubation time (24 h) combined with the highest con-
centrations of MNPs. Compared to the control, no signifi-
cant differences in cellular viability were observed; only 
15 μg/ml of P-MNPs incubated for 6 h was found to be 
slightly reduced (p < 0.05).
In Vivo Validation of P127- and T908-Coated 
Superparamagnetic Nanoparticles for Cell Detection
On the basis of the excellent in vitro MRI detection 
capabilities of labeled cells, we assessed the in vivo 
detection after transplantation of P-MNP- and T-MNP-
tagged and nontagged MSCs cells in the rat brain 
Figure 3. Transmission electron microscopy (TEM) images of 
labeled MSCs. (A) MSCs labeled with P-MNPs (35 μg/ml, 24 h). 
(B) C17.2 labeled with P-MNPs (35 μg/ml, 24 h). (C) MSCs 
labeled with T-MNPs (35 μg/ml, 24 h). (D) C17.2 labeled with 
T-MNPs (35 μg/ml, 24 h). Black arrows indicate organelles 
filled with MNPs. Abbreviations: MSCs, mesenchymal stem 
cells; C17.2, multipotent neural progenitor cell line from mice; 
P-MNPs, pluronic F127-coated superparamagnetic nanoparticles; 
T-MNPs, tetronic 908-coated superparamagnetic nanoparticles.
Table 1. Iron Content per Cell (pg) Deter mined by 
ICP-OES After Labeling Compared With Control
MSCs C17.2
Control 0.4 (0.1) 0.4 (0.0)
P-MNPs
35 μg/ml 24 h 36.8 (1.4) 28.0 (7.0)
15 μg/ml 24 h 16.2 (0.4) 9.7 (0.8)
35 μg/ml 6 h 39.0 (3.0) 33.0 (3.0)
15 μg/ml 6 h 8.9 (0.5) 12.7 (0.8)
T-MNPs
35 μg/ml 24 h 37.0 (3.0) 39.0 (1.0)
15 μg/ml 24 h 9.9 (1.5) 14.0 (2.0)
35 μg/ml 6 h 36.0 (4.0) 16.7 (1.5)
15 μg/ml 6 h 12.4 (1.4) 8.0 (3.0)
Values are mean with SD in parentheses. Two incu-
bation times (6 h and 24 h) and two concentrations 
of MNPs in medium (35 μg/ml and 15 μg/ml) were 
studied. ICP-OEs, inductive coupled plasma optical 
emission spectroscopy; MNPs, superparamagnetic 
nanoparticles; P-MNPs, pluronic F127-coated super-
paramagnetic nanoparticles; T-MNPs, tetronic 908-
coated superparamagnetic nanoparticles.
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following an intraparenchymal administration. No MRI 
signal was detected for 5 × 104 unlabeled cells in either 
animal (Figs. 7A and 8A); however, the needle trace 
can be observed after the delivery of P-MNP-labeled 
MSCs (red asterisk in Fig. 7A). On the other hand, the 
hypointensity observed in the right hemispheres cor-
responded to 5 × 104 labeled MSCs (Figs. 7A and 8A). 
Immunofluorescence of brains after cell transplantation 
was performed to assess the colocalization of labeled 
MSCs and the generated MRI hypointensity, observed by 
CFSE fluorescence microscopy, Prussian blue staining, 
and T2*-weighted images, respectively (Figs. 7 and 8). 
CFSE-labeled MSCs were found in both hemispheres 
(Figs. 7D and E and 8D and E), but positive staining 
for Prussian blue was only observed for P-MNP- and 
T-MNP-labeled cells (Figs. 7C and 8C), evidencing the 
colocalization of MSCs, P-MNPs, or T-MNPs and MR 
T2* contrast generated.
Figure 4. Cellular iron internalization and MRI signal generated. (A) Intracellular iron determined by ICP-OES after different label-
ing conditions in MSCs (**p < 0.001 with respect to control cells). (B) Intracellular iron determined by ICP-OES after different 
labeling conditions in C17.2 (**p < 0.001 with respect to control cells). (C) Relaxation rates R2* of MSCs after different labeling 
conditions (*p < 0.05 respect to control cells). (D) Relaxation rates R2* of C17.2 after different labeling conditions (**p < 0.001 with 
respect to control cells). (E) Magnetic resonance (MR) T2*-weighted images of labeled MSC s and C17.2 embedded in a phantom 
for cell detection. All conditions show the presence of hypointense spots of labeled MSCs and C17.2, respectively, in the first echo of 
MGE T2*-weighted scans with a cell density of 500 cells/μl. Abbreviations: MRI, magnetic resonance imaging; ICP-OES, inductive 
coupled plasma optical emission spectroscopy; MSCs, mesenchymal stem cells; C17.2, multipotent neural progenitor cell line from 
mice; MGE, multigradient echo sequence.
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DISCUSSION
MRI combined with superparamagnetic nanoparticles 
is a powerful tool for studying the biodistribution of trans-
planted cells. The sensitivity of cell detection is mainly 
determined by two parameters: (i) composition of the 
core of the MNPs and (ii) the amount of MNPs internal-
ized. This last factor is governed by size (6) and shape of 
the particles (14), but also by their surface functionaliza-
tion (46), which largely regulates the interactions between 
the nanoparticles and the cells; nevertheless, special care 
must be taken to preserve the cellular functions of the 
labeled cells, since the migration of the administered 
cells remains interesting from a therapeutic point of view. 
MNP internalization is not a trivial issue, and therefore 
several strategies such as the use of transfection agents 
(1,4,23,28,42), cationic lipids (46), specific peptide func-
tionalization (33), or electroporation (13,49) have been 
explored to increase the cellular uptake. In this work, we 
have refrained from using the above-mentioned methods 
and assessed the cell-labeling efficacies of P127- and 
T908-coated superparamagnetic nanoparticles (MNPs).
P-MNPs and T-MNPs were synthesized following 
a procedure described by Jain et al. (21), who initially 
developed P-MNPs as potential drug carrier systems for 
anticancer agents. The chemical coprecipitation method 
used for the magnetic nanoparticle synthesis is consid-
ered the easiest method to produce superparamagnetic 
nanoparticles. The main limitations of this method are 
the influences of several parameters such as temperature, 
pH, presence of oxygen in the reaction, stirring speed, 
Fe3+/Fe2+ molar ratio, and ammonium hydroxide addition 
process on the final particle size (31). The MNP cores 
obtained in this work are spherical shaped with a circular-
ity of 0.87, a value close to 1, which represents a perfect 
circle. This value together with stable core sizes (about 
8 nm) determined by three different techniques (TEM, 
XRD, and DLS) and with numerical values consistent with 
previous studies (21,34) makes this synthesis a reliable 
and easy procedure for obtaining MNPs. The XRD analy-
sis exhibited typical magnetite peaks, indicating that the 
black-colored suspension obtained are magnetite nano-
particles, and VSM results showed their superparamag-
netic behavior at RT. Within the synthesis, OA was added 
to create a hydrophobic OA shell surrounding the nano-
particle core, which will be used as an anchor for further 
polymer functionalization. The interaction between the 
OA and the iron oxide core can be classified in three fun-
damental structures (34) depending on the wave number 
Figure 5. MGE-MRI signal decay for phantoms loaded with MSCs after 35 μg/ml and 15 μg/ml P-MNP incubation for 24 h. T2* maps 
were calculated by fitting pixel intensities of the multigradient echo images to a monoexponential decay curve on a pixel-by-pixel basis.
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separation (Dn0) between the nas(COO–) and the ns(COO–) 
from FTIR. In the present study, this value was 170 cm−1, 
which indicated the existence of a bidentate structure and 
confirmed that the OA was chemisorbed onto the core as 
a surfactant; however, the FTIR peak for polymer-coated 
MNPs was in 1100 cm−1. This demonstrated the presence 
of the copolymers in the coated-stabilized MNPs (12,21). 
The differences in size from the core (8 nm) and the 
coated nanoparticles (154 nm for pluronic-coated MNPs 
and 180 nm for tetronic-coated MNPs) could indicate 
that there are no single cores coated. To assess the trans-
verse relaxivity measured by MRI and their suitability 
as MRI contrast agents, T2 maps were calculated. Our r2 
[398 ± 12 mM−1 s−1 (P127) and 330 ± 20 mM−1 s−1 (T908)] 
are higher than similar commercial nanoparticles such 
as Resovist or Endorem, which dispersed in water and 
have r2 values from 54 to 185 L/mmol−1 s−1, depending 
on the magnetic field (0.47–4.7 T) (40). The difference 
between these commercial nanoparticles and our MNPs 
could be due only to the different medium in which the 
NPs were dissolved or the different magnetic field used 
for the analysis. Considering their size, composition, and 
dispersion stability in water, P-MNPs and T-MNPs were 
found to be suitable candidates for biological applications 
such as being used to tag cells for further MRI detection.
Cell tagging with P-MNPs and T-MNPs was per-
formed by simple incubation of the particles with the 
target cells, MSCs and C17.2, and the selection of our 
MNP incubation times and concentrations was based on 
previous calibration tests (data not shown).
After MNP incubation, the cellular uptake must be 
complete, with all MNPs fully internalized (in contrast 
to membrane-bound MNPs), to obtain an unequivocal 
MRI signal from labeled cells and not from free particles 
or host macrophages that have internalized the MNPs 
(15,17). For this, a previously described internalization 
procedure (48) was followed, and TEM images of labeled 
cells demonstrated a complete internalization for all con-
ditions studied. This easy incubation procedure for cell 
labeling was concentration dependent for P-MNPs and 
T-MNPs, but not incubation time dependent after 6 h, as 
reflected by the ICP-OES data. This dependence helps 
Figure 6. Cellular well-being after labeling. (A) MSC proliferation after labeling compared to control calculated through cell count. 
(B) C17.2 proliferation after labeling compared to control. (C) MSC viability determined by LDH after labeling compared to control. 
(D) C17.2 viability determined by LDH after labeling compared to control. *p < 0.05; **p < 0.01; ***p < 0.001. Abbreviations: MSCs, 
mesenchymal stem cells; C17.2, multipotent neural progenitor cell line from mice; P-MNPs, pluronic F127-coated superparamagnetic 
nanoparticles; T-MNPs, tetronic 908-coated superparamagnetic nanoparticles; LDH, lactate dehydrogenase assay.
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in the understanding of the internalization mechanism. 
The interaction between the MNPs and the cells could be 
mediated by gravitational forces (sedimentation) instead 
of surface attraction (5). In this way, after 6 h of incu-
bation, P-MNPs and T-MNPs could be deposited onto 
the cell surface, facilitating the labeling; extending the 
incubation for 18 h more would not result in any differ-
ence regarding the amount of MNPs internalized. It is 
important to note that the aforementioned sedimentation 
did not lead to MNP aggregation during incubation since 
non-MNP conglomeration was observed in any case. 
The same concentrations of MNPs incubated for 6 or 
24 h with MSCs or C17.2 showed similar values of iron 
internalization, about 30–40 pg/cell, which is in concert 
with previous reports, showing an increase in iron uptake 
up until 8 h (45). These values of internalized MNPs 
are significantly higher than published data of commer-
cial nanoparticles Endorem, combined with transfection 
agents (poly-l-lysine) in MSCs, being less than 20 pg/cell 
for MNP incubation medium (from 50 to 200 μg/ml) and 
24-h labeling time (28,39,48). However, a direct com-
parison between P-MNPs and T-MNPs with ferumoxides 
(Endorem) and ferucarbotran (Resovist), under the same 
experimental conditions, was not possible since they are 
not produced anymore by the pharmaceutical industry 
(29). Labeled cells were visualized in MRI phantoms at 
Figure 7. In vivo and ex vivo analysis of rat brain after an 
intraparenchymal administration of CFSE-labeled and P-MNP-
CFSE labeled MSCs. (A) First echo of T2*-weighted images 
of a rat brain slice after intraparenchymal administration of 
CFSE-labeled MSCs in the left hemisphere and CFSE- and 
P-MNP-labeled MSCs in the right hemisphere. (B) Phase-
contrast optical microscopy of a brain section after Prussian 
blue staining of CFSE-labeled MSCs. (C) Phase-contrast opti-
cal microscopy of a brain section after Prussian blue staining of 
CFSE- and P-MNP-labeled MSCs. (D) Fluorescent microscopy 
of same brain section as (B). (E) Fluorescence microscopy of a 
brain section after Prussian blue staining of CFSE- and P-MNP-
labeled MSCs. Fluorescence microscopy of same brain section 
as (C). Scale bars: 100 μm. Abbreviations: MSCs, mesenchymal 
stem cells; P-MNPs, pluronic F127-coated superparamagnetic 
nanoparticles; CFSE, CellTracer CFSE Cell Proliferation Kit 
for flow cytometry.
Figure 8. In vivo and ex vivo analysis of rat brain after an intra-
parenchymal administration of CFSE-labeled and T-MNP-CFSE 
labeled MSCs. (A) First echo of T2*-weighted images of a rat 
brain slice after intraparenchymal administration of CFSE-labeled 
MSCs in the left hemisphere and CFSE- and T-MNP-labeled 
MSCs in the right hemisphere. (B) Phase contrast optical micros-
copy of a brain section after Prussian blue staining of CFSE-
labeled MSCs. (C) Phase contrast optical microscopy of a brain 
section after Prussian blue staining of CFSE- and T-MNP-labeled 
MSCs. (D) Fluorescent microscopy of same brain section as (B). 
(E) Fluorescence microscopy of a brain section after Prussian 
blue staining of CFSE- and T-MNP-labeled MSCs, Fluorescence 
microscopy of same brain section as (C). Scale bar 100 μm. 
Abbreviations: MSCs, mesenchymal stem cells; T-MNPs, tetronic 
908-coated superparamagnetic nanoparticles; CFSE, CellTracer 
CFSE Cell Proliferation Kit for flow cytometry.
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a density of 500 cells/μl to compare the results to those 
of other studies (28,48). Moreover, labeled cells can be 
visualized by MRI due to their effect on the local mag-
netic field, subsequently reducing the intensity of the sig-
nal in MGE sequences. Differences in gray scale could 
be observed and correlated to internalized iron; however, 
quantitative differences in R2* values were marginal due 
to the already strong contrast generated by low amounts 
of MNP-labeled cells. Therefore, the signal on the second 
echo MRI signal was almost fully eliminated, hampering 
a quantitative R2* estimation, as can be noted in Figure 
5. In brief, a cell incubation with 35 μg of P-MNPs or 
T-MNPs, not longer than 6 h, was enough to obtain an 
efficient cell labeling, which demonstrates the efficacy of 
the protocol described.
Looking at the effect of P-MNPs and T-MNPs on cell 
behavior, longer incubation times and a greater amount 
of particles in medium did show a reduction in the cell 
count after the coincubation, which was not reflected by 
a decrease in viability. Cell count of MSCs and C17.2 
was reduced, but cell death was not increased, as demon-
strated by the LDH results. Previous studies have found that 
MNPs can interfere with cell viability assays, such as LDH 
or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (18,30). To avoid this interaction, in this 
study, the supernatants from labeled and nonlabeled cells 
after 12-h incubation with fresh medium were centrifuged, 
and pellets were discarded. In addition to this viability 
determination, no morphological or structural changes 
were observed by TEM. Moreover, labeled and unlabeled 
cells were harvested several times to perform Prussian blue 
staining. No differences in cell adhesion or morphological 
changes were detected after 8 h between groups, confirm-
ing the well-being of MNP-labeled cells despite a decrease 
in the cell count after incubation. Our work shows a prom-
ising labeling technique for the study of the in vivo biodis-
tribution of stem cells without side effects; however, for a 
further therapeutic study with these tagged cells, it will be 
necessary to address the viability beyond 36 h. Otherwise, 
we have to understand the use of nanoparticles for cell 
tracking as an experimental tool to characterize the in vivo 
cell distribution and not as a clinical technique. Therefore, 
potential interaction between nanoparticles and cells on 
differentiation or proliferation long term is not relevant in 
this stage.
So far, we showed that P-MNPs and T-MNPs can be 
successfully used for in vitro cell tagging and detection 
in agar phantoms for MRI. Therefore, in a final step of 
P-MNP and T-MNP characterization as contrast agents for 
cell detection by MRI, an in vivo intraparenchymal deliv-
ery of MNP-labeled and unlabeled cells was performed. 
Intraparenchymal delivery route has been one of the most 
commonly used administration routes for several patholo-
gies such as glioma (35), stroke (7,25,32), Parkinson’s 
disease (37), etc., and the monitoring possibilities of 
injected cells would contribute to establishing the relation-
ship between cellular biodistribution, migration, and out-
come (26). Thus, MNP-labeled cells were administered in 
the right hemisphere, and MRI hypointensity was observed 
in T2*-weighted images, where a strong R2* effect due to 
the iron presence was noted. In the contralateral hemi-
sphere, unlabeled but an identical number of cells was 
administered. No signal differences were observed for 
unlabeled cells compared to normal brain tissue. It should 
be noted that the needle trace can be easily observed in the 
cortex, assessing the correct administration localization.
To correlate the in vivo MRI results with the presence 
of MNP-labeled cells and unlabeled cells, ex vivo analysis 
of brain tissue was performed by Prussian blue staining 
for MNP detection and fluorescence microscopy exami-
nation of CFSE-labeled cells. MRI hypointense signals 
were observed in T2*-weighted MR images in the right 
hemisphere of the brain, which corresponded with posi-
tive Prussian blue staining and positive CFSE labeling, 
confirming that the P-MNPs and T-MNPs were still com-
partmentalized in the cells several hours after the admin-
istration. The cells without MNP labeling did not exhibit 
any contrast in T2*-weighted MRI nor in Prussian blue 
staining. However, the needle trace and CFSE-positive 
signal were observed, confirming their correct adminis-
tration. The in vivo detection of labeled cells following 
an intraparenchymal injection in healthy animals was 
successfully addressed in this study, and it was confirmed 
that P-MNPs and T-MNPs are contrast agent complexes 
that can be used to assess the biodistribution of therapeu-
tic cells after an intraparenchymal injection with high 
sensitivity. A further study of biodistribution following 
intravenous or intra-arterial administration routes in ani-
mal models of ischemic stroke or Alzheimer disease, for 
example, would help in elucidating the promising thera-
peutic effects that stem cells offer.
CONCLUSION
The present study assessed the use of P-MNPs and 
T-MNPs as contrast agents for MRI cell tracking in vivo. 
Cell tagging was performed by a simple coincubation of 
MNPs with the target cells, leading to an efficient and 
full MNP internalization without the need for transfection 
agents or other sophisticated approaches. The uptake was 
dependent up MNP concentration, and the cell labeling 
was performed with short incubation time periods. This 
may reduce possible side effects of excessive preculture, 
thus making this technique accessible for preclinical 
studies. In addition, we validated the in vivo detection 
of transplanted cells after an intraparenchymal adminis-
tration in T2*-weighted MR images and correlated it to 
ex vivo cellular and MNP detection, evidencing that the 
contrast generated in MRI corresponds to labeled cells 
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and not to free particles. P-MNPs and T-MNPs are easy-
to-use labels for enabling MRI tracking of transplanted 
therapeutic cells in the brain, but their use could also be 
extended to other organs or tissues.
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